🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsRetatrutide & Triple AgonistsTriple agonist sounds scary - is it actually safe — looking for input

Triple agonist sounds scary - is it actually safe — looking for input

Dr.PulmRoch Mon, Oct 27, 2025 at 9:12 PM 12 replies 1,132 viewsPage 1 of 3
This thread is more than 7 months old. Information may be outdated. Consider searching for more recent discussions.
Dr.PulmRoch
Member
456
2,345
Jun 2024
Rochester, MN
Oct 27, 2025 at 9:12 PM#1

Reading the retatrutide phase 2 data properly rather than the headline, and the 24% figure is doing a lot of work that the confidence interval does not support as firmly as people think.

For anyone tracking the class: GLP-1 alone gets you appetite, GLP-1 plus GIP adds tolerability and lipid handling, and adding glucagon adds expenditure and liver-fat reduction. Each addition also adds a receptor system that can generate side effects.

What I am trying to establish is why adding glucagon agonism to an anti-obesity drug is not self-defeating, given that glucagon raises blood glucose.

Not looking for reassurance. Looking for the part I have got wrong.

20 15rachel_ABQ, traveltech_sara, AttorneyGrant and 17 others
Reply Quote Save Share Report
DataDave
Senior Member
1,678
8,901
Apr 2024
Washington
Online
Oct 27, 2025 at 9:24 PM#2

Answering the narrow version, because the broad one does not have a single answer. The mechanism and the magnitude are separate questions. Agreeing that something happens says nothing about whether it happens enough to act on.

19 14mike_nyc, VendorMark, COA_Karl and 16 others
Reply Quote Save Share Report
MikeNYC_runner
Member
378
1,678
Jul 2024
New York, NY
Oct 27, 2025 at 9:36 PM#3
DataDave said:
The mechanism and the magnitude are separate questions.

DataDave has the substance of this right. The condition it depends on is worth stating. The glucagon component looks paradoxical and is not. Glucagon receptor agonism raises energy expenditure and drives hepatic fatty-acid oxidation, and its hyperglycaemic tendency is offset by the GLP-1 arm's insulin secretagogue effect. Net result: intake down from GLP-1/GIP, expenditure up from glucagon, glycaemia neutral or improved. It is a balancing act, and it is why the liver-fat results are the most interesting part of the dataset.

Last edited: Oct 27, 2025 at 11:36 PM
18 13Dr.ObesityMed, HealthEcon_DC, PedsEndoPhilly and 15 others
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides

GL Biochem (Shanghai) Ltd. — Direct Manufacturer

Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.

Browse GL Biochem
tyler_CSCS
Member
567
2,567
Jun 2024
Phoenix, AZ
Oct 27, 2025 at 9:48 PM#4
Dr.PulmRoch said:
Reading the retatrutide phase 2 data properly rather than the headline, and the 24% figure is doing a lot of work that the confidence interval does…

Mine went the same way, slower.

17 12amy_econ_NJ, bbq_ray_KC, oliver_london and 14 others
Reply Quote Save Share Report
NurseKim_ATL
Senior Member
1,678
7,234
Feb 2024
Atlanta, GA
Oct 27, 2025 at 10:49 PM#5

Clinical perspective, offered as context rather than as advice. It helps to say which part of this you are uncertain about. A precise question gets a precise answer; a general one gets everybody’s favourite anecdote.

16 11hank_denver, carlos_SATX, sophie_paris and 13 others
Reply Quote Save Share Report

Similar Threads

TRIUMPH-3 topline results — 24.2% body weight loss at 48 weeks10 replies
Retatrutide mechanism: GLP-1/GIP/glucagon triple agonism explained5 replies
Retatrutide Phase 2 dose-response analysis — optimal dose range10 replies
Glucagon receptor agonism and hepatic lipid oxidation — MASH implications13 replies
Retatrutide vs tirzepatide — dual vs triple agonist comparison22 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register